share_log

CRISPR Therapeutics | 10-Q: Q3 2024 Earnings Report

SEC ·  Nov 5 09:16

Summary by Moomoo AI

CRISPR Therapeutics, a leader in gene editing technology, has reported significant developments in its financial and operational activities as of September 30, 2024. Financially, the company has not generated revenue from product sales and does not anticipate doing so in the near future. However, it has recognized a small amount of grant revenue. The company's operating expenses have decreased, with research and development expenses dropping to $238.5 million from $292.2 million in the previous year. General and administrative expenses also saw a reduction. CRISPR Therapeutics has deferred $44.9 million in costs for the CASGEVY program under a collaboration with Vertex, compared to a deferral of $23.4 million in the previous year. The company's net loss has increased year-over-year, with a loss of...Show More
CRISPR Therapeutics, a leader in gene editing technology, has reported significant developments in its financial and operational activities as of September 30, 2024. Financially, the company has not generated revenue from product sales and does not anticipate doing so in the near future. However, it has recognized a small amount of grant revenue. The company's operating expenses have decreased, with research and development expenses dropping to $238.5 million from $292.2 million in the previous year. General and administrative expenses also saw a reduction. CRISPR Therapeutics has deferred $44.9 million in costs for the CASGEVY program under a collaboration with Vertex, compared to a deferral of $23.4 million in the previous year. The company's net loss has increased year-over-year, with a loss of $328.9 million compared to $242.9 million. In terms of business development, CRISPR Therapeutics has made strides with its flagship CRISPR/Cas9-based therapy, CASGEVY, which has been approved in multiple countries for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. The company is also advancing several other gene-edited cell therapy programs for oncology and autoimmune diseases, as well as in vivo editing programs for cardiovascular disease. Looking ahead, CRISPR Therapeutics plans to continue its research and development efforts, with a focus on expanding clinical trials, advancing current programs, and identifying new product candidates. The company expects to incur increased expenses as it progresses with its development activities and prepares for potential commercialization of its product candidates.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated